Literature DB >> 6594235

The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.

G L Drusano, H C Standiford, C I Bustamante, A Forrest, G Rivera, B Tatem, S C Schimpff.   

Abstract

The plasma pharmacokinetics of imipenem, a beta-lactam antibiotic of the new class of carbapenems, was evaluated by administering 1 g imipenem plus 1 g of the dehydropeptidase inhibitor cilastatin to six healthy male volunteers over 30 min. Subsequently intensive plasma sampling was done for 5.5 h. The volume of distribution of the central compartment was 0.16 +/- 0.04 1/kg; the volume of distribution (area) was 0.28 +/- 0.07 1/kg; the volume of distribution (steady state) was 0.23 +/- 0.03 1/kg. The mean plasma clearance was 10.1 +/- 1.0 1/h/1.73 m2. Model-independent analysis showed excellent agreement with these values. The terminal excretion half-life was short (1.3 +/- 0.4 h). For approximately 6 h after administration, the observed plasma levels were above those required to inhibit most nosocomial pathogens in vitro.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594235     DOI: 10.1007/bf02017377

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  7 in total

1.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

2.  Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability.

Authors:  D A Gravallese; D G Musson; L T Pauliukonis; W F Bayne
Journal:  J Chromatogr       Date:  1984-09-14

3.  Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

Authors:  S R Norrby; K Alestig; F Ferber; J L Huber; K H Jones; F M Kahan; M A Meisinger; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

4.  Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

Authors:  S R Norrby; K Alestig; B Björnegård; L A Burman; F Ferber; J L Huber; K H Jones; F M Kahan; J S Kahan; H Kropp; M A Meisinger; J G Sundelof
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

5.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.

Authors:  J E Brown; V E Del Bene; C D Collins
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

  7 in total
  10 in total

1.  Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Pharmacokinetics of imipenem-cilastatin in serum and tissue.

Authors:  A Kümmel; V Schlosser; E Petersen; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

Review 3.  [Pharmacokinetics and antimicrobial activity of imipenem].

Authors:  G A Dette; H Knothe
Journal:  Infection       Date:  1986       Impact factor: 3.553

4.  Imipenem/cilastatin.

Authors:  M Barza
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 5.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  [Effect and tolerance of daily 2 X 1 g imipenem/cilastatin in general surgery].

Authors:  M Wenzel; H Loch
Journal:  Infection       Date:  1986       Impact factor: 3.553

7.  Tentative interpretive criteria for in vitro antibacterial susceptibility testing with imipenem.

Authors:  D L Shungu; A T Cerami; E Weinberg; T Capizzi; H H Gadebusch
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

8.  [Bone concentrations of imipenem after a dose of imipenem/cilastatin].

Authors:  D H Wittmann; T H Kuipers; R Fock; M Höll; A Bauernfeind
Journal:  Infection       Date:  1986       Impact factor: 3.553

9.  Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.

Authors:  Samir G Sakka; Anna K Glauner; Jürgen B Bulitta; Martina Kinzig-Schippers; Wolfgang Pfister; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

10.  [Calculated initial chemotherapy in mechanically-ventilated postoperative patients with peritonitis, sepsis and pneumonia].

Authors:  G Hünefeld; H Weissbrodt; H Aebert; H Bunzendahl
Journal:  Infection       Date:  1986       Impact factor: 3.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.